Infectious complications of systemic sclerosis;Complications infectieuses de la sclérodermie systémique

Presse Medicale

Volumn 38, Issue 2, 2009, Pages 291-302

  Bussone, Guillaume ^a   Berezné, Alice ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INFECTION COMPLICATION; INTENSIVE CARE UNIT; INTERSTITIAL LUNG DISEASE; LUNG TRANSPLANTATION; OPPORTUNISTIC INFECTION; PROGNOSIS; RARE DISEASE; SHORT SURVEY; SKIN ULCER; SYSTEMIC SCLEROSIS;

BACTERIAL INFECTIONS; CALCINOSIS; HUMANS; INFECTION; PROGNOSIS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 58949098417     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.11.003     Document Type: Short Survey

References (87)

1. Tamby M.C., Chanseaud Y., Guillevin L., and Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2 (2003) 152-157
2. Servettaz A., Agard C., Tamby M.C., Guilpain P., Guillevin L., and Mouthon L. Physiopathologie de la sclérodermie systémique : état des lieux sur une affection aux multiples facettes. Presse Med 35 (2006) 1903-1915
3. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (1988) 202-205
4. LeRoy E.C., and Medsger Jr. T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 28 (2001) 1573-1576
5. Mayes M.D., Lacey Jr. J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48 (2003) 2246-2255
6. Roberts-Thomson P.J., and Walker J.G. Scleroderma: it has been a long hard journey. Intern Med J 36 (2006) 519-523
7. Tamaki T., Mori S., and Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283 (1991) 366-371
8. Magnant J., and Diot E. Sclérodermie systémique : épidémiologie et facteurs environnementaux. Presse Med 35 (2006) 1894-1901
9. Le Guern V., Mahr A., Mouthon L., Jeanneret D., Carzon M., and Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 43 (2004) 1129-1137
10. Steen V.D., and Medsger Jr. T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437-2444
11. Steen V.D., and Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 (2007) 940-944
12. Steen V.D., and Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthr Rheum 41 (1998) 1613-1619
13. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6 (2000) 1183-1186
14. Lunardi C., Dolcino M., Peterlana D., Bason C., Navone R., Tamassia N., et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3 1 (2006) e2
15. Muryoi T., Kasturi K.N., Kafina M.J., Cram D.S., Harrison L.C., Sasaki T., et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 175 (1992) 1103-1109
16. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 81 (2002) 154-167
17. Arias-Nunez M.C., Llorca J., Vazquez-Rodriguez T.R., Gomez-Acebo I., Miranda-Filloy J.A., Martin J., et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine 87 (2008) 272-280
18. Hesselstrand R., Scheja A., and Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57 (1998) 682-686
19. Ruangjutipopan S., Kasitanon N., Louthrenoo W., Sukitawut W., and Wichainun R. Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis. J Med Assoc Thai 85 (2002) 1204-1209
20. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine 81 (2002) 139-153
21. Foeldvari I., Zhavania M., Birdi N., Cuttica R.J., de Oliveira S.H., Dent P.B., et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 39 (2000) 556-559
22. Ranque B., Authier F.J., Berezne A., Guillevin L., and Mouthon L. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 1108 (2007) 268-282
23. Ward M.M., and Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42 (1999) 780-789
24. Clements P.J., Goldin J.G., Kleerup E.C., Furst D.E., Elashoff R.M., Tashkin D.P., et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 50 (2004) 1909-1917
25. Lanternier F., Henegar C., Mouthon L., Blanche P., Guillevin L., and Launay O. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 67 (2008) 1047
26. Mouthon L., Mestre C., Poiraudeau S., Berezné A., Marchand C., Guilpain P., et al. Low influenza-vaccination rate among systemic sclerosis patients. Annual European Congress of Rheumatology. EULAR 2008 Paris, France. Ann Rheum Dis 67 (2008) 363
27. Pando J., and Nashel D.J. Clinical images: progressive calcifications and draining lesions following staphylococcal infection in a patient with limited scleroderma. Arthritis Rheum 41 (1998) 373
28. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34 (2007) 2423-2430
29. Nihtyanova S.I., Brough G.M., Black C.M., and Denton C.P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67 (2008) 120-123
30. Marie I. Atteinte digestive au cours de la sclérodermie systémique. Presse Med 35 (2006) 1952-1965
31. Sjogren R.W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37 (1994) 1265-1282
32. Gough A., Andrews D., Bacon P.A., and Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol 34 (1995) 976-977
33. Domsic R., Fasanella K., and Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 53 (2008) 1163-1174
34. Kaye S.A., Lim S.G., Taylor M., Patel S., Gillespie S., and Black C.M. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 34 (1995) 265-269
35. Wegener M., Adamek R.J., Wedmann B., Jergas M., and Altmeyer P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 39 (1994) 2209-2215
36. Attar A., Flourie B., Rambaud J.C., Franchisseur C., Ruszniewski P., and Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117 (1999) 794-797
37. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
38. Centers for disease control and prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56:170-2.
39. Brown M., Teubner A., Shaffer J., and Herrick A.L. Home parenteral nutrition--an effective and safe long-term therapy for systemic sclerosis-related intestinal failure. Rheumatology (Oxford) 47 (2008) 176-179
40. Dhote R., Simon J., Papo T., Detournay B., Sailler L., Andre M.H., et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 49 (2003) 633-639
41. Godeau B., Mortier E., Roy P.M., Chevret S., Bouachour G., Schlemmer B., et al. Short and longterm outcomes for patients with systemic rheumatic diseases admitted to intensive care units: a prognostic study of 181 patients. J Rheumatol 24 (1997) 1317-1323
42. Shalev T., Haviv Y., Segal E., Ehrenfeld M., Pauzner R., Levy Y., et al. Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheumatol 24 (2006) 380-386
43. Camargo J.F., Tobon G.J., Fonseca N., Diaz J.L., Uribe M., Molina F., et al. Autoimmune rheumatic diseases in the intensive care unit: experience from a tertiary referral hospital and review of the literature. Lupus 14 (2005) 315-320
44. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., Rasker J.J., van Lier H.J., and van de Putte L.B. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 (1996) 364-372
45. Pope J.E., Bellamy N., Seibold J.R., Baron M., Ellman M., Carette S., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001) 1351-1358
46. Dheda K., Lalloo U.G., Cassim B., and Mody G.M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 23 (2004) 306-309
47. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 (2006) 3962-3970
48. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006) 2655-2666
49. Vanthuyne M., Blockmans D., Westhovens R., Roufosse F., Cogan E., Coche E., et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25 (2007) 287-292
50. Nihtyanova S.I., Brough G.M., Black C.M., and Denton C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 46 (2007) 442-445
51. Walz B.H., and Crosby L.A. Mycobacterium avium-intracellulare infection of the knee joint. Case report. Am J Knee Surg 8 (1995) 35-37
52. Ferry A.P., Font R.L., Weinberg R.S., Boniuk M., and Schaffer C.L. Nocardial endophthalmitis: report of two cases studied histopathologically. Br J Ophthalmol 72 (1988) 55-61
53. Clements P.J., Lachenbruch P.A., Sterz M., Danovitch G., Hawkins R., Ippoliti A., et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36 (1993) 75-83
54. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., and Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20 (1993) 838-844
55. Akesson A., Scheja A., Lundin A., and Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37 (1994) 729-735
56. Steen V.D., Lanz Jr. J.K., Conte C., Owens G.R., and Medsger Jr. T.A. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37 (1994) 1290-1296
57. Varai G., Earle L., Jimenez S.A., Steiner R.M., and Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25 (1998) 1325-1329
58. Davas E.M., Peppas C., Maragou M., Alvanou E., Hondros D., and Dantis P.C. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18 (1999) 455-461
59. White B., Moore W.C., Wigley F.M., Xiao H.Q., and Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132 (2000) 947-954
60. Pakas I., Ioannidis J.P., Malagari K., Skopouli F.N., Moutsopoulos H.M., and Vlachoyiannopoulos P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29 (2002) 298-304
61. Giacomelli R., Valentini G., Salsano F., Cipriani P., Sambo P., Conforti M.L., et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29 (2002) 731-736
62. Griffiths B., Miles S., Moss H., Robertson R., Veale D., and Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29 (2002) 2371-2378
63. Kowal-Bielecka O., Kowal K., Rojewska J., Bodzenta-Lukaszyk A., Siergiejko Z., Sierakowska M., et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 64 (2005) 1343-1346
64. Ostojic P., and Damjanov N. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumatol 25 (2006) 819-821
65. Airo P., Danieli E., Rossi M., Frassi M., Cavazzana I., Scarsi M., et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25 (2007) 293-296
66. Beretta L., Caronni M., Raimondi M., Ponti A., Viscuso T., Origgi L., et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 26 (2007) 168-172
67. Yiannopoulos G., Pastromas V., Antonopoulos I., Katsiberis G., Kalliolias G., Liossis S.N., et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatology international 27 (2007) 357-361
68. Berezne A., Ranque B., Valeyre D., Brauner M., Allanore Y., Launay D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35 (2008) 1064-1072
69. D'Angelo S., Cuomo G., Paone C., Colutta E., La Montagna G., and Valentini G. Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. Clin Rheumatol 22 (2003) 393-396
70. Calguneri M., Apras S., Ozbalkan Z., Ertenli I., Kiraz S., Ozturk M.A., et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22 (2003) 289-294
71. Nadashkevich O., Davis P., Fritzler M., and Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25 (2006) 205-212
72. Valentini G., Paone C., La Montagna G., Chiarolanza I., Menegozzo M., Colutta E., et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scandinavian journal of rheumatology 35 (2006) 35-38
73. Filaci G., Cutolo M., Scudeletti M., Castagneto C., Derchi L., Gianrossi R., et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 38 (1999) 992-996
74. Paone C., Chiarolanza I., Cuomo G., Ruocco L., Vettori S., Menegozzo M., et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25 (2007) 613-616
75. Stratton R.J., Wilson H., and Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40 (2001) 84-88
76. Liossis S.N., Bounas A., and Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45 (2006) 1005-1008
77. Gerbino A.J., Goss C.H., and Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 (2008) 455-460
78. Massad M.G., Powell C.R., Kpodonu J., Tshibaka C., Hanhan Z., Snow N.J., et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 29 (2005) 1510-1515
79. Levine S.M., Anzueto A., Peters J.I., Calhoon J.H., Jenkinson S.G., and Bryan C.L. Single lung transplantation in patients with systemic disease. Chest 105 (1994) 837-841
80. Schachna L., Medsger Jr. T.A., Dauber J.H., Wigley F.M., Braunstein N.A., White B., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54 (2006) 3954-3961
81. Kubo M., Vensak J., Dauber J., Keenan R., Griffith B., and McCurry K. Lung transplantation in patients with scleroderma. J Heart Lung Transplant 20 (2001) 174-175
82. Pham P.T., Pham P.C., Danovitch G.M., Gritsch H.A., Singer J., Wallace W.D., et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 5 (2005) 2565-2569
83. Tyndall A., and Gratwohl A. Immune ablation and stem-cell therapy in autoimmune disease. Clinical experience. Arthritis Res 2 (2000) 276-280
84. Binks M., Passweg J.R., Furst D., McSweeney P., Sullivan K., Besenthal C., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60 (2001) 577-584
85. Farge D., Passweg J., van Laar J.M., Marjanovic Z., Besenthal C., Finke J., et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 63 (2004) 974-981
86. van Laar J.M., Farge D., and Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 64 (2005) 1515
87. Vonk M.C., Marjanovic Z., van den Hoogen F.H., Zohar S., Schattenberg A.V., Fibbe W.E., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67 (2008) 98-104